[1]Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet, 2006, 368 (9553): 2142-2154.[2]Wright A, Zignol M, Van Deun A, et al. Epidemiology of antituberculosis drug resistance 2002—07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet, 2009, 373 (9678): 1861-1873.[3]王胜芬, 赵冰, 宋媛媛, 等. 我国耐药结核病的危险因素——2007年全国结核病耐药基线调查资料分析. 中国防痨杂志, 2013, 35(4): 221-226.[4]肖和平. 抗结核药物的合理使用是控制耐药结核病流行的基石. 中华结核和呼吸杂志, 2014, 37(10):723-724.[5]唐神结.耐药结核病综合治疗的回顾与展望.结核病与肺部健康杂志,2014,3(3):141-147.[6]曾熙玲,初乃惠,刘志敏.耐药结核病辅助治疗的进展. 结核病与肺部健康杂志,2013,2(4):222-227.[7]马晓薇, 胡忠义, 王洁, 等. 噬菌体法与 BACTEC-960 检测结核分枝杆菌乙胺丁醇耐药性的比较研究. 中华内科杂志, 2005, 44 (3): 202-205.[8]Krüüner A, Yates MD, Drobniewski FA. Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first-and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis. J Clin Microbiol, 2006, 44 (3): 811-818.[9]Adjers-Koskela K, Katila ML. Susceptibility testing with the manual mycobacteria growth indicator tube (MGIT) and the MGIT 960 system provides rapid and reliable verification of multidrug-resistant tuberculosis. J Clin Microbiol, 2003, 41 (3): 1235-1239.[10]张楠, 胡继红, 赵秀芹, 等. 比例法药敏试验检测乙胺丁醇耐药适合药物浓度的初步探讨. 中国人兽共患病学报, 2009, 25(11): 1049-1053.[11]中国防痨协会基础专业委员会.结核病诊断实验室检验规程. 北京: 中国教育文化出版社,2006.[12]Leonard B, Coronel J, Siedner M, et al. Inter-and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis.J Clin Microbiol, 2008, 46 (10): 3526-3529.[13]World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Geneva:World Health Organization,2009.[14]李立明. 流行病学.5版.北京:人民卫生出版社,2003.[15]蔡杏珊, 张院良, 谭耀驹. 三种不同方法检测结核分枝杆菌药物敏感性分析. 国际医药卫生导报, 2010, 16 (9): 1092-1096.[16]Mariam DH, Mengistu Y, Hoffner SE, et al. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother, 2004, 48 (4): 1289-1294.[17]Chauca JA, Palomino JC, Guerra H. Evaluation of the accuracy of the microplate Alamar Blue assay for rapid detection of MDR-TB in Peru. Int J Tuberc Lung Dis, 2007, 11 (7): 820-822.[18]程松,李园园,胡忠义,等. 基因测序检测embB基因诊断结核分枝杆菌乙胺丁醇耐药性的Meta分析. 中国防痨杂志, 2014,36(11): 958-965. |